IDXX$629.35
$629.2
Chart
Performance
Key Stats
AI IDXX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyIDEXX Laboratories demonstrates strong fundamental performance with consistent growth and profitability. Thematic tailwinds in animal health and diagnostics are supportive. Technical indicators are mixed, suggesting a potentially overbought short-term condition but a strong long-term uptrend.
Thematic
IDEXX is well-positioned in the growing companion animal health and veterinary diagnostics market. Trends in pet humanization and increased spending on pet care provide sustained tailwinds.
Fundamental
IDEXX exhibits robust financial health with consistent revenue and earnings growth, strong profitability, and a healthy balance sheet. The company has no dividend yield, indicating a focus on reinvestment for growth.
Technical
The stock exhibits a strong upward trend on daily and longer-term charts. However, short-term indicators suggest it may be approaching overbought conditions, hinting at a potential for a temporary pause or pullback.
| Factor | Score |
|---|---|
| Companion Animal Health Spending | 85 |
| Veterinary Diagnostics Market | 80 |
| Technology Integration in Vet Practices | 75 |
| Livestock and Poultry Health | 50 |
| Water Testing Industry | 40 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 85 |
| Growth | 75 |
| Earnings Per Share (EPS) | 80 |
| Balance Sheet Health | 70 |
| Cash Flow | 85 |
| Dividends | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 85 |
| Momentum | 65 |
| Volume | 70 |
| Support & Resistance | 75 |
| Short-term Oscillators | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Consistent Earnings Beat
IDEXX Laboratories (IDXX) has consistently beaten EPS estimates for the past several quarters, with a recent Q2 2025 surprise of 3.75% (reported $2.96 vs. estimate $2.85). This indicates strong operational execution and effective management.
Reasonable P/E for Growth
The P/E ratio (TTM) of 63.9, while seemingly high, should be considered in context with the company's growth. The annual P/E ratio for 2024 was 37.4, and for 2023 was 52.3, showing a declining trend. Analyzing the P/E to Growth (PEG) ratio would provide further insight, but the current performance suggests the valuation might be justifiable given its earnings trajectory.
Bearish Points (7)
High Forward P/E
Quarterly P/E ratios for 2024 are significantly elevated (e.g., Q1 2025 at 139.2, Q4 2024 at 153.8). While trailing P/E ratios are lower, these forward multiples suggest that the market is pricing in substantial future growth, potentially leading to overvaluation if growth expectations are not met.
Slowing Quarterly Revenue Growth
While annual revenue shows growth, quarterly revenue figures show some deceleration. For instance, Q2 2024 revenue was $1.003 billion with a 20.3% net margin, compared to Q1 2025 revenue of $998 million with a 24.3% net margin, indicating potential lumpiness or a slowdown in immediate growth drivers.
Calendar
August 2025
4
Next Earnings Date
H: $3.35
A: $3.30
L: $3.26
H: 1.08B
A: 1.07B
L: 1.06B
Profile
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, it offers diagnostic tests, services, and related instrumentation for manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Seasonals
Price Target
524.16 USD
The 39 analysts offering 1 year price forecasts for IDXX have a max estimate of 625.00 and a min estimate of 385.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in animal health pharmaceuticals, vaccines, and diagnostics, serving a similar veterinary market to IDEXX.
Weight: 90
Major animal health pharmaceutical company offering a wide range of products for companion and food animals, often directly comparable to IDEXX in market focus.
Weight: 88
Key direct competitor specializing in point-of-care veterinary diagnostics, imaging, and software, directly competing with IDEXX's core offerings.
Weight: 80
Provides diagnostic solutions for animal safety, food safety, and genomics, with significant overlap in diagnostic technology and target markets (especially livestock and poultry).